Verona Pharma is off to a promising start as it launches its first product, Ohtuvayre, a maintenance treatment for chronic obstructive pulmonary disorder (COPD). In 2024, Ohtuvayre generated sales of $42 million, the company reported on Tuesday. More: Verona touts 'exceptionally
read more
OAV101 IT expands potential for type II SMA patients More: Novartis gene therapy set to enhance SMA treatment Source: News
read more
M-Trust set to improve product safety and counterfeiting solutions More: Merck unveils new cyber-physical trust platform at CES 2025 Source: News
read moreGlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of
read moreWith COVID vaccine sales in the doldrums and an RSV vaccine market in “contraction”, Moderna CEO Stéphane Bancel had the unenviable task of trying to put a positive spin on a sharp stock decline in his annual shareholder letter. More:
read moreFor the second year in a row, Bausch + Lomb has joined with the Glaucoma Research Foundation to launch the “Faces of Glaucoma” campaign during January’s Glaucoma Awareness Month. More: Bausch + Lomb re-ups 'Faces of Glaucoma' campaign to raise
read more© 1994 - 2026 B.M. Pharmaceuticals